Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron

References

• NICE. Guide to the methods of health technology appraisal. London: National Institute of Health and Clinical Excellence, 2008
   Google Scholar
• Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72
   PubMed Web of Science ®Google Scholar
• Parkin D, Rice N, Devlin N. Statistical analysis of EQ-5D profiles: does the use of value sets bias inference? Med Decis Making 2010;30:556-65
   Web of Science ®Google Scholar
• Brazier J, Akehurst R, Brennan A, et al. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy 2005;4:201-8
   PubMedGoogle Scholar
• Feng Y, Parkin D, Devlin N. An investigation of issues arising from the EQ-VAS in the NHS PROMs programme. OHE Research Paper 12/01. London: Office of Health Economics, 2011
   Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2012;189:1388-95
   Google Scholar
• Devlin NJ, Parkin D, Browne J. Patient-reported outcome measures in the NHS: new methods for analysing and reporting EQ-5D data. Health Econ 2010;19:886-905
   PubMed Web of Science ®Google Scholar
• Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med 1999;44:56-66
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-78
   PubMed Web of Science ®Google Scholar
• Chapple CR. Alpha-adrenergic blocking drugs in bladder outflow obstruction: what potential has alpha 1-adrenoceptor selectivity? Br J Urol 1995;76(1 Suppl):47-55
   Google Scholar
• Haylen BT, de RD, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4-20
   PubMed Web of Science ®Google Scholar
• Irwin DE, Kopp ZS, Agatep B, et al. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132-8
   PubMed Web of Science ®Google Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306-14
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009;104:352-60
   PubMed Web of Science ®Google Scholar
• Basra R, Kelleher C. Disease burden of overactive bladder: quality-of-life data assessed using ICI-recommended instruments. Pharmacoeconomics 2007;25:129-42
   PubMed Web of Science ®Google Scholar
• Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 2011;60:784-95
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Nishizawa O, Takeda M, et al. Clinical guidelines for overactive bladder. Int J Urol 2009;16:126-42
   PubMed Web of Science ®Google Scholar
• D'Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008;14:291-301
   PubMed Web of Science ®Google Scholar
• Benner JS, Nichol MB, Rovner ES, et al. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 2010;105:1276-82
   PubMed Web of Science ®Google Scholar
• Chapple CR, Yamaguchi O, Ridder A, et al. Clinical proof of concept study (blossom) shows novel beta 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Journal Eur Urol Suppl 2008;7:674
   Google Scholar
• Chapple CR, Wyndaele JJ, Van Kerrebroeck P, et al. 774 Dose-ranging study of once-daily mirabegron (YM178), a novel selective beta-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol Suppl 2010;9:249
   Web of Science ®Google Scholar
• Kind P, Brooks R, Rabin R. EQ-5D concepts and methods: a developmental history. The Netherlands: Springer, 2005
   Google Scholar
• Szende A, Oppe M, Devlin N. EQ-5D value sets: inventory, comparative review and user guide. 2nd ed. The Netherlands: Springer, 2006
   Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-108
   PubMed Web of Science ®Google Scholar
• Greiner W, Weijnen T, Nieuwenhuizen M, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 2003;4:222-31
   PubMedGoogle Scholar
• Coyne KS, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002;11:563-74
   PubMed Web of Science ®Google Scholar
• Matza LS, Thompson CL, Krasnow J, et al. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn 2005;24:215-25
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Kopp Z, et al. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006;49:1079-86
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101:1388-95
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Pitman R, Tincello D, et al. Cost-effectiveness of duloxetine: the Stress Urinary Incontinence Treatment (SUIT) study. Value Health 2010;13:565-72
   Google Scholar
• Kobelt G, Fianu-Jonasson A. Treatment of stress urinary incontinence with non-animal stabilised hyaluronic acid/dextranomer (NASHA/Dx) gel: an analysis of utility and cost. Clin Drug Investig 2006;26:583-91
   Google Scholar
• Ternent L, Vale L, Buckley B, et al. Measuring outcomes of importance to women with stress urinary incontinence. BJOG 2009;116:719-25
   Google Scholar
• Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727-36
   PubMed Web of Science ®Google Scholar